Trastuzumab ensured the specificity to HER2-positive cells and enabled the UCNP-ZnPc-Tras to selectively reduce the viability of breast cancer cells to 21% after 5 min of exposure to infrared light. This evidence concerns the gene ERBB2 and breast carcinoma.